People with hormone-relapsed prostate cancer that has spread to other parts of the body and have been treated with the cytotoxic drug docetaxel, should be given access to enzalutamide through the NHS, NICE has confirmed in final draft guidance. Enzalutamide is also known as Xtandi and manufactured by Astellas Pharma.

In previous draft recommendations NICE had not recommended enzalutamide in the group of people that had previously been treated with abiraterone. Following the response to consultation on previous draft recommendations NICE this has been removed from the guidance recommendations.

For more details, go to: http://www.nice.org.uk/newsroom/pressreleases/NICEIssuesFinalDraftGuidanceRecommendingEnzalutamideForProstateCancer.jsp